louisakewell, Author at European Medical Journal - Page 65 of 153

EMJ

Changing the treatment landscape of metastatic melanoma

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Axel Hauschild, MD, from University of Kiel, Kiel, Germany…

EMJ

Clinical decision-making for pancreatic cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Thomas Seufferlein, MD, from University of Ulm, Ulm, Germany…

EMJ

The significance of BRCA mutations in pancreatic cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Thomas Seufferlein, MD, from University of Ulm, Ulm, Germany…

EMJ

Treatment of pancreatic cancer: Overview of the continued progress

Pancreatic cancer is a leading cause of cancer-related deaths in developed countries. At the German Cancer Congress 2016, held in Berlin, Germany, from…

Daratumumab (DARZALEX®) Combination Therapy Significantly Extended Progression-Free Survival in Previously Treated Patients with Multiple Myeloma

Beerse, Belgium, 5 June 2016 – Data from the Phase 3 MMY3004 (CASTOR) clinical trial show the immunotherapy daratumumab (DARZALEX®) in combination with a…

Helsinn Group Hosts a Satellite Symposium on Shared Decision Making in Supportive Care, at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Annual Meeting 2016 on June 24th

Lugano, Switzerland, June 13, 2016 – Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that it is…

The DA-EPOCH-R clinical trial in Burkitt’s lymphoma

Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA, gives an overview of the interim analysis of a multicenter prospective…

New Janssen Phase 3 Data in Patients with Moderately to Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression and Improves Signs and Symptoms of Disease

London, United Kingdom, 8 June, 2016 – Janssen Research & Development, LLC (Janssen) announced today results from a pivotal Phase 3 study evaluating…

New Data Demonstrates Sandoz’ Etanercept and Rituximab Biosimilar Candidates Bioequivalent to Originator Products

Holzkirchen, June 9 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from two key studies…

Artificial Hip Joints and Obesity: Risk of Complications Rises with BMI but Benefits Predominate

Geneva, 2 June 2016 – Every tenth patient who receives an artificial hip joint in Europe is obese. This is a big challenge for orthopaedic surgery…